Dr. Scott Aaronson specializes in treatment-resistant affective disorders. He is a thought leader in the areas of biological psychiatry, diagnosis and the integration of somatic and psychological therapies. As director of clinical research programs at Sheppard Prat, he is the principal investigator for multiple studies on the development of novel therapies for mood, anxiety and psychotic disorders. Dr. Aaronson is a valued speaker and educator and frequently lectures, regionally and nationally, on mood disorders, including integration of biological and psychotherapies, complex mood disorders, psychoeducation and the development of new therapies. He also provides diagnostic and psychopharmacological consultation.

Dr. Aaronson currently serves as an adjunct professor of psychiatry at the University of Maryland School of Medicine, fellow of the American College of Psychiatrists and distinguished life fellow of the American Psychiatric Association. Dr. Aaronson also serves as the Chief Science Officer of the Sheppard Pratt Institute for Advanced Diagnostics and Therapeutics. Additionally, he works as a psychiatrist at The Retreat at Sheppard Pratt, a premiere, self-funded psychiatric setting.

Education

Dr. Aaronson received his MD from Harvard Medical School and his BA from Columbia University.

Dr. Aaronson has nearly 20 years of experience treating patients with affective disorders at the New England Psychiatric Group, a clinic he founded, and at McLean Hospital, Newton-Wellesley Hospital and Saint Anne’s Hospital. He also taught psychiatry at Harvard Medical School. In 1981, Dr. Aaronson was the recipient of the Sergay Sanger Award for excellence in psychiatric research.